Sunnybrook Health Sciences Centre
Quick facts
| Founded | 1948 |
|---|
Marketed products
- Acetylsalicylic Acid (ASA) · Cardiovascular; Pain management; Inflammation
Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation. - citalopram (celexa) · Psychiatry / Mental Health
Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. - Methoxyflurane, MEOF · Anesthesia, Acute Pain Management
Methoxyflurane is a volatile halogenated ether anesthetic that depresses the central nervous system to produce anesthesia and analgesia. - Perflutren lipid microsphere
- Placebo (cornstarch)
Placebo (cornstarch) has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect. - Sevoflurane inhalant product · Anesthesiology
Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling. - ticagrelor + aspirin · Cardiovascular
Ticagrelor and aspirin work together to prevent blood clots by inhibiting platelet activation and aggregation through different pathways. - Withania somnifera
Phase 3 pipeline
- Cholinesterase Inhibitor · Neurology
Cholinesterase inhibitors block the enzyme that breaks down acetylcholine, allowing acetylcholine to accumulate in the synapse and enhance cholinergic neurotransmission. - hypertonic saline mixed Dextran · Critical Care
Hypertonic saline mixed Dextran works by increasing blood volume and improving blood flow to vital organs. - Isoflurane Inhalant Product · Anesthesiology
Isoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory neurotransmission and suppressing excitatory pathways, producing unconsciousness and analgesia. - Magnesium sulfate and then Digoxin · Cardiovascular
Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction. - modified PENTOCLO (mPENTOCLO) · Infectious Disease
Modified PENTOCLO is a pentamidine-based compound designed to enhance antimicrobial or antiparasitic activity through structural optimization. - No tranexamic acid · Hematology / Hemostasis
Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, reducing fibrin degradation and promoting blood clot stability. - r-HuEPO · Oncology, Nephrology
r-HuEPO is a recombinant form of human erythropoietin that stimulates red blood cell production. - sham mPENTOCLO · Cardiovascular
Pentosan polysulfate sodium is an anticoagulant that works by inhibiting the coagulation cascade. - Variation in volume of local anesthetic · Anesthesiology / Pain Management
This is a clinical trial protocol studying how different volumes of local anesthetic affect clinical outcomes, rather than a drug with a defined molecular mechanism.
Phase 2 pipeline
- Alpha Interferon · Oncology, Infectious Diseases
Alpha Interferon works by stimulating the body's immune system to fight viral infections and cancer. - Daily TMZ
- Definity Suspension for Injection · Cardiovascular
Definity Suspension for Injection is a microbubble ultrasound contrast agent that enhances the visualization of cardiac structures and function. - Lenalidomide and melphalan
- QBECO
- Y90 Ibritumomab Tiuxetan RIT
Phase 1 pipeline
- Bupivacaine hydrogen chloride , epinephrine
- PERT at discharge
- Plasma HPV
- prostaglandin of the clinician's choice
- Ropivacaine 1%
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Sunnybrook Health Sciences Centre portfolio CI brief
- Sunnybrook Health Sciences Centre pipeline updates RSS
Frequently asked questions about Sunnybrook Health Sciences Centre
What are Sunnybrook Health Sciences Centre's marketed drugs?
Top marketed products include Acetylsalicylic Acid (ASA), citalopram (celexa), Methoxyflurane, MEOF, Perflutren lipid microsphere, Placebo (cornstarch), Sevoflurane inhalant product.
What is Sunnybrook Health Sciences Centre's pipeline?
Sunnybrook Health Sciences Centre has 9 drugs in Phase 3, 6 in Phase 2, 5 in Phase 1. Late-stage candidates include Cholinesterase Inhibitor, hypertonic saline mixed Dextran, Isoflurane Inhalant Product, Magnesium sulfate and then Digoxin.
When was Sunnybrook Health Sciences Centre founded?
Sunnybrook Health Sciences Centre was founded in 1948.
How many employees does Sunnybrook Health Sciences Centre have?
Sunnybrook Health Sciences Centre has approximately 6,349 employees.
Related
- Acetylsalicylic Acid (ASA) · Cardiovascular; Pain management; Inflammation
- citalopram (celexa) · Psychiatry / Mental Health
- Methoxyflurane, MEOF · Anesthesia, Acute Pain Management
- Perflutren lipid microsphere
- Placebo (cornstarch)
- Sector hub: All tracked pharma companies